MétaCan
Menu
Back to cohort
Record W4415773240 · doi:10.25251/tvshr813

The role of interleukin-13 in the management of atopic dermatitis: An expert consensus panel

2025· article· en· W4415773240 on OpenAlexfundno aff
Lauren DeBusk, Natasha Atanaskova-Mesinkovska, Brooke Bartley, Joshua Burshtein, Michael D. Cameron, Theodore J. Daly, Lawrence F. Eichenfield, Dawn A. Merritt, Tejesh Patel, Darrell S. Rigel, Angela Rosenberg, Milaan Shah, Lisa Swanson, Danny Zakria, Mark Lebwohl

Bibliographic record

VenueDermatology Online Journal · 2025
Typearticle
Languageen
FieldMedicine
TopicDermatology and Skin Diseases
Canadian institutionsnot available
FundersGenentechLEO PharmaBausch HealthCastle BiosciencesIncyteUCB PharmaSun PharmaRegeneron PharmaceuticalsGaldermaBristol-Myers SquibbEli Lilly and CompanyAstraZenecaAmgenMeiji Seika PharmaPfizerCelltrionAbbVieSanofiNational Alopecia Areata Foundation
KeywordsAtopic dermatitisDelphi methodDupilumabDelphiMEDLINEAlternative medicineCornerstoneImmune Dysfunction

Abstract

fetched live from OpenAlex

Atopic dermatitis is a chronic inflammatory skin condition driven by immune dysregulation, with interleukin-13 playing a central role in its pathogenesis. Recent advances in targeted biologic therapies have shown promising results in treating moderate-to-severe atopic dermatitis. A comprehensive literature review of PubMed and Google Scholar was conducted to identify studies related to interleukin-13 inhibition in atopic dermatitis. An expert panel reviewed and graded the evidence using Strength of Recommendation Taxonomy criteria and utilized a modified Delphi process to formulate consensus statements on the role of interleukin-13 inhibitors. Based on selected literature, the panel developed 14 consensus statements, all receiving unanimous approval. Key findings include the rapid efficacy, sustained benefits, and favorable safety profiles of interleukin-13 inhibitors. Differences between available interleukin-13 inhibitors included pain of injection, speed of onset, durability of efficacy, and number of injections needed to maintain efficacy. Interleukin-13 plays a pivotal role in atopic dermatitis pathogenesis, driving inflammation, pruritus, and barrier dysfunction. Targeted therapies, including interleukin-13 inhibitors, provide rapid, durable, and safe options for managing moderate-to-severe atopic dermatitis. This consensus highlights interleukin-13 inhibition as a cornerstone in advancing atopic dermatitis treatment strategies, offering improved patient outcomes and quality of life.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.090
metaresearch head score (Gemma)0.106
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.090
Threshold uncertainty score0.476

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0900.106
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.006
Bibliometrics0.0070.004
Science and technology studies0.0020.001
Scholarly communication0.0040.004
Open science0.0050.005
Research integrity0.0080.008
Insufficient payload (model declined to judge)0.0040.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.312
Teacher spread0.295 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueDermatology Online JournalSame topicDermatology and Skin DiseasesFrench-language works237,207